Answer
Xeplion (paliperidone palmitate) is not recommended for patients with moderate or severe renal impairment, defined as creatinine clearance below 50 mL/min.
Sources for this answer
- XEPLION 150 mg prolonged release suspension for injectionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.2 Posology and method of administration · Version 4Document updated
Sources checked